MedTrace Logo

Cat-PAD Exposure Chamber Study

NCT01033344 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2010-10-01

No results posted yet for this study

Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy.

This study will look at the efficacy, safety and tolerability of two doses of Cat-PAD in cat allergic subjects following challenge to cat allergen in an EEC.

Conditions

  • Cat Allergy

Interventions

BIOLOGICAL

Placebo

Intradermal injection 1x8 administrations 2 weeks apart

BIOLOGICAL

Cat-PAD

Intradermal injection 1x8 administrations 2 weeks apart

BIOLOGICAL

Cat-PAD

Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo

Sponsors & Collaborators

  • Adiga Life Sciences, Inc.

    collaborator INDUSTRY

  • Cetero Research, San Antonio

    collaborator NETWORK

  • Circassia Limited

    lead INDUSTRY

Principal Investigators

  • Deepen Patel, MD, CCF · Cetero Research, San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01033344 on ClinicalTrials.gov